Clinical Trial Update: Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating rapamycin for secondary prevention in patients with resected non-muscle invasive bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Bladder Cancer | Phase 3 | Status: WITHDRAWN